Latest Biotech News

Insilico Medicine announced the selection of ISM5059, a peripheral‑restricted NLRP3 inhibitor discovered using generative AI platforms, as its lead preclinical candidate. The company reported that...

Generate:Biomedicines, a Flagship Pioneering‑backed biotech that applies machine learning to antibody and protein engineering, filed to go public while advancing an anti‑TSLP antibody into Phase 3...

Researchers unveiled NEO‑STIM, a platform that refines neoantigen‑specific adoptive T‑cell therapy by improving selection and stimulation of patient‑specific tumor antigens. The...

More than two years after FDA approval, Vertex’s CRISPR‑based sickle‑cell therapy Casgevy has treated only about 60 patients globally, with centers reporting difficulty collecting sufficient cells...

Belgian immunology developer Agomab Therapeutics and ocular drug delivery company SpyGlass Pharma priced listings on Nasdaq, collectively raising about $350 million. Agomab secured roughly $200...

Eikon Therapeutics completed an upsized Nasdaq offering that raised $381 million, marking the largest biotech IPO since 2024. The San Francisco oncology company plans to direct proceeds toward...

Veradermics raised $256 million in an IPO to fund three pivotal trials of its oral minoxidil candidate for pattern hair loss. The New Haven-based company positioned the offering to advance phase...

Generate:Biomedicines, the Flagship-backed platform that uses AI to design protein therapeutics, filed for an IPO as it advances phase 3 and earlier-stage antibody and CAR-T programs. The filing...

Eli Lilly reported results and guidance that outpaced Wall Street expectations, driven by fast-selling GLP-1 medicines, while rival Novo Nordisk issued a downbeat 2026 sales outlook that sent its...

Telehealth provider Hims & Hers started selling a compounded version of Novo Nordisk’s newly approved Wegovy oral formulation, prompting Novo to threaten litigation and regulatory action. Hims...

The administration launched TrumpRx, a consumer-facing portal powered by GoodRx technology to display cash prices for prescription drugs and direct patients to purchase options. Officials pitched...

The FDA re-examined historical trial adjudication data for Tavneos (avacopan) and requested withdrawal; Amgen rejected the agency’s request and said it will continue discussions. The FDA’s action...

Bayer reported Phase 3 results showing asundexian, a factor XIa inhibitor, reduced recurrent ischemic stroke by about 26% without added safety signals, improving the commercial and clinical...

Angitia Biopharmaceuticals closed a $130 million Series D to progress three biologics targeting musculoskeletal diseases into mid‑stage development. The round positions the US‑China company to...

Eikon Therapeutics priced an upsized $381 million initial public offering and will begin trading under ticker EIKN. The company raised the proceeds to advance a clinical-stage oncology portfolio...

Generate:Biomedicines, the Flagship Pioneering–backed AI-driven antibody biotech, filed to go public and is pitching its programmable-biology platform and late-stage asthma asset to investors. The...

Telehealth provider Hims & Hers began selling a compounded pill version of Novo Nordisk’s Wegovy, prompting immediate industry and regulatory blowback. Novo has threatened litigation, calling the...

Bayer reported that its factor XIa inhibitor asundexian reduced ischemic stroke recurrence by 26% in a large phase 3 study, without adding major safety signals. The company released details after...

BARDA opened a $100 million prize competition to accelerate development of broad-spectrum small-molecule antivirals targeting Togaviridae and Flaviviridae families. The multi-stage program aims to...

Illumina is leaning further into healthcare markets after disruptions to NIH funding under the Trump administration rattled basic-research demand for sequencing. Company comments and earnings show...